Two conferences in Riga and Vilnius bring science, policy and investment together to address healthspan and aging populations.
Healthy longevity is moving into the political mainstream of Northern Europe. September will see two significant gatherings in the Baltics, both bringing the subject of aging and healthspan into the corridors of power. On 16–17 September, the 3rd International Baltic Conference on Healthy Longevity takes place in Riga, hosted at Riga Technical University and drawing participation from the OECD, ministry of health and leading clinicians, health officials and researchers. Just days later, on 19 September, Vilnius will host the International Conference Towards Healthy Longevity in the Parliament of the Republic of Lithuania, the Seimas, with ministers, parliamentarians and senior academics joining forces with international experts.
The Baltic region is facing a pressing demographic reality; life expectancy in both Lithuania and Latvia hovers at 76 years, but healthy life expectancy sits closer to 64, among the lowest in the EU and OECD. During the pandemic the decline in life expectancy in both countries was among the sharpest in Europe, reflecting the vulnerability of older citizens and the challenge of ensuring not just longer lives, but healthier ones.
Longevity.Technology: The Baltics are not just convening another talking shop; with life expectancy hovering around 76 years and healthy life expectancy stuck near 64 – plus some of the EU’s sharpest COVID-era reversals – Latvia and Lithuania present a clear, urgent test case for delivering gains in healthspan where it matters most. The twin gatherings in Riga and at the Seimas set a tone that longevity is graduating from lab curiosity to strategic priority; if organizers can convert these stages into cross-border data standards, procurement pilots and reimbursable prevention, they will do more for the field’s credibility than a dozen white papers. Policy anchoring tends to unlock capital – parliamentary venues and explicit sessions on regulation and data signal to founders and investors that the door is open for biotech, AI and diagnostics to build here rather than elsewhere. Ultimately this is about more than extra years; it is about independence, productivity and dignity in aging societies – the conferences can supply the applause, but it is the attendees who must ensure they turn it into funded action.
Science and systems on the agenda
Both conferences have been co-organized by the International Longevity Alliance, Vetek (Seniority) Association and Longevity Alliance Baltic, and the programs show a conscious effort to bridge science and policy. In Riga, Ilia Stambler of Vetek will address how research, development, education and policy can be aligned for healthy longevity, while the OECD’s Wouter De Tavernier will set out the organization’s framework for healthy aging. The European Health Data Space is also on the agenda, with Didier Coeurnelle of HEALES examining how health data can be shared to accelerate progress.
The Vilnius program reflects similar priorities but with the weight of parliamentary setting. Lithuanian speakers include Algirdas Utkus, Chairman of the National Health Council, addressing genetic testing and aging trajectories, and Mindaugas Valius, Head of the Proteomics Center at Vilnius University, exploring breakthroughs in rejuvenation technologies. International contributions range from Jesper Eugen-Olsen of ViroGates on suPAR as a biomarker of healthspan to Richard W Barker of King’s College London on regulatory pathways for emerging therapies.
From biomarkers to biopsychosocial factors
Both conferences balance molecular biology with wider determinants of health. In Riga, sessions will address reproductive longevity, hormone therapy, digital health engagement and the role of the microbiome. In Vilnius, presentations cover regenerative surgery, cognitive evaluation, and psychological as well as biomolecular influences on the biological clock. This breadth reflects a recognition that longevity cannot be achieved solely through pharmacology or biotech – education, health literacy and social infrastructure are equally crucial.
Economics and investment
For policymakers, longevity is also an economic question. The Riga meeting will include Sebastian Brunemeier of Long Game Ventures on the venture capital perspective, while Vilnius will host discussion on the cost of longevity and the role of private investment in prevention. Positioning longevity as a driver of resilience and productivity, rather than as a cost burden, is essential if finance ministries and investors are to be engaged alongside clinicians and researchers.
A Baltic test case
The Baltic region is smaller than many of its EU peers, but this may be an advantage; data-driven pilot schemes and regulatory innovations can be trialled at scale more easily in smaller populations. Both Lithuania and Latvia face steep demographic challenges with aging populations and declining overall numbers, so effective longevity policy is not a luxury but a necessity. If the momentum from these meetings results in new programs of prevention, diagnostics and therapeutics, the Baltics could become a model for other regions wrestling with similar demographic pressures.
A forward motion
The two conferences will convene different audiences but a common theme runs through them – longevity is no longer a fringe pursuit, it is being taken seriously as science, as policy and as investment. Whether that seriousness translates into action will depend less on the speeches made and more on what participants build together afterwards; as always, the measure of success will be what follows once the conference lights are switched off.
3rd International Baltic Conference on Healthy Longevity, 16–17 September, Riga Technical University, Riga, Latvia.
International Conference Towards Healthy Longevity, 19 September, the Seimas, Vilnius, Lithuania.
